The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial (Q44344781)

2 December 2017

The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial (English)

1 reference

nicotine replacement therapy

2 December 2017

0 references

0 references

1 reference

Lerman C

1

1 reference

2 December 2017

Wileyto EP

2

1 reference

2 December 2017

Patterson F

3

1 reference

2 December 2017

Rukstalis M

4

1 reference

2 December 2017

Audrain-McGovern J

5

1 reference

2 December 2017

Restine S

6

1 reference

2 December 2017

Shields PG

7

1 reference

2 December 2017

Kaufmann V

8

1 reference

2 December 2017

Redden D

9

1 reference

2 December 2017

Benowitz N

10

1 reference

2 December 2017

Berrettini WH

11

1 reference

2 December 2017

1 January 2004

1 reference

The Pharmacogenomics Journal

2 December 2017

1 reference

2 December 2017

4

1 reference

2 December 2017

3

1 reference

2 December 2017

184-192

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500238

2 December 2017

0 references

cites work

A potent and selective endogenous agonist for the mu-opiate receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

A genetic association study of the mu opioid receptor and severe opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Nicotine medications for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Pharmacology of nicotine: addiction and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Population stratification and spurious allelic association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Use of unlinked genetic markers to detect population stratification in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Mediating mechanisms for the impact of bupropion in smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Plasma nicotine, plasma beta-endorphin and mood states during periods of chronic smoking, abstinence and nicotine replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Noise stress does not modulate effects of smoking/nicotine on beta-endorphin, cortisol, ACTH, glucose, and mood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Neuroendocrine reactivity to nicotine in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

State-dependent modulation of feeding behavior by proopiomelanocortin-derived beta-endorphin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

A Role for the Endogenous Opioid β-Endorphin in Energy Homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Genetic relationship between central beta-endorphin and novelty-induced locomotor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Prolonged nicotine patch use in quitters with past abstinence-induced depressed mood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Smoking cessation among inner-city African Americans using the nicotine transdermal patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

CYP2A6 genetic variation and potential consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Randomised controlled trial of nasal nicotine spray in smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

The need for dissemination of evidence-based results from research on nicotine and tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

Development and validation of brief measures of positive and negative affect: The PANAS scales

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Gender differences in smoking cessation

2 references

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

21 January 2018

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Nicotine delivery kinetics and abuse liability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Absolute bioavailability of nicotine applied to different nasal regions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Nicotine replacement therapy for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Biochemical verification of tobacco use and cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Application of serum nicotine and plasma cotinine concentrations to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500238

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500238

1 reference

2 December 2017

1 reference